Worth reading
47Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
1153600
Shares (plus an over-allotment of up to 173,000 shares)Wording
Conditional
How definitive the wording is.Details of issuance or disposal
Secondary offering of shares (secondary offering through purchase underwriting by underwriters) and secondary offering through an over-allotment
発行・処分する株式数
Secondary offering through purchase underwriting by the underwriters: 1,153,600 shares; secondary offering through an over-allotment: up to 173,000 shares
Intended allottee
No specific allottees. Selling agent: Mitsubishi UFJ Morgan Stanley Securities Co., Ltd. Initial sellers of the shares: 大正製薬ホールディングス株式会社 and Sumitomo Pharma Co.,Ltd.
Terms of the stock acquisition rights
Exercise period
Greenshoe option: from the settlement date of the secondary offering through purchase underwriting by the underwriters and the secondary offering through an over-allotment until 23 April 2026 (Thursday)
Conditions on transfer restrictions
Restricted stock is stock awarded as compensation that cannot be sold during a specified period, with the restrictions lifted once the applicable conditions are met.
Transfer restriction period
180 days (the lock-up period begins on the offering price determination date and ends on the 180th day from the settlement date of the secondary offering through purchase underwriting by the underwriters)
Conditions for lifting transfer restrictions
With the prior written consent of Mitsubishi UFJ Morgan Stanley Securities Co., Ltd. The securities company may, at its discretion, release the agreement during the period.
Offering structure
Underwriter / lead underwriter
Mitsubishi UFJ Morgan Stanley Securities Co., Ltd. (lead manager) and the underwriting syndicate
Overallotment
Up to 173,000 offered shares. The additional acquisition right under the greenshoe option is also limited to 173,000 shares.
Basis for determining the amount to be paid
The indicative price range will be set at 0.90 to 1.00 times the closing price for regular trading on the Tokyo Stock Exchange on the offering price determination date, with the final price determined after taking demand conditions into account.
Most recent equity financing
September 2025: underwriting of a private placement by アンドファーマ株式会社 and acquisition of shares, making it an equity-method affiliate. Amount: Not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | Secondary offering of shares (secondary offering through purchase underwriting by underwriters) and secondary offering through an over-allotment |
| Number of shares to be issued or disposed of | Secondary offering through purchase underwriting by the underwriters: 1,153,600 shares; secondary offering through an over-allotment: up to 173,000 shares |
| Intended allottee | No specific allottees. Selling agent: Mitsubishi UFJ Morgan Stanley Securities Co., Ltd. Initial sellers of the shares: 大正製薬ホールディングス株式会社 and Sumitomo Pharma Co.,Ltd. |
| Basis for determining the amount to be paid | The indicative price range will be set at 0.90 to 1.00 times the closing price for regular trading on the Tokyo Stock Exchange on the offering price determination date, with the final price determined after taking demand conditions into account. |
| Exercise period | Greenshoe option: from the settlement date of the secondary offering through purchase underwriting by the underwriters and the secondary offering through an over-allotment until 23 April 2026 (Thursday) |
| Transfer restriction period | 180 days (the lock-up period begins on the offering price determination date and ends on the 180th day from the settlement date of the secondary offering through purchase underwriting by the underwriters) |
| Conditions for lifting transfer restrictions | With the prior written consent of Mitsubishi UFJ Morgan Stanley Securities Co., Ltd. The securities company may, at its discretion, release the agreement during the period. |
| Underwriter / lead underwriter | Mitsubishi UFJ Morgan Stanley Securities Co., Ltd. (lead manager) and the underwriting syndicate |
| Overallotment | Up to 173,000 offered shares. The additional acquisition right under the greenshoe option is also limited to 173,000 shares. |
| Most recent equity financing | September 2025: underwriting of a private placement by アンドファーマ株式会社 and acquisition of shares, making it an equity-method affiliate. Amount: Not disclosed |
Items this document does not state (18)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyDilution RateTotal number of issued sharesExercise priceNumber of Stock Acquisition RightsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In response to shareholders' intention to sell their cross-shareholdings, to improve the liquidity of the Company's shares and enable individual investors who understand and support the Company's long-term strategy to hold them.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.